| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FLJ12875 |
| Uniprot No | Q969V5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-352aa |
| 氨基酸序列 | MESGGRPSLCQFILLGTTSVVTAALYSVYRQKARVSQELKGAKKVHLGEDLKSILSEAPGKCVPYAVIEGAVRSVKETLNSQFVENCKGVIQRLTLQEHKMVWNRTTHLWNDCSKIIHQRTNTVPFDLVPHEDGVDVAVRVLKPLDSVDLGLETVYEKFHPSIQSFTDVIGHYISGERPKGIQETEEMLKVGATLTGVGELVLDNNSVRLQPPKQGMQYYLSSQDFDSLLQRQESSVRLWKVLALVFGFATCATLFFILRKQYLQRQERLRLKQMQEEFQEHEAQLLSRAKPEDRESLKSACVVCLSSFKSCVFLECGHVCSCTECYRALPEPKKCPICRQAITRVIPLYNS |
| 分子量 | 64.46 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人FLJ12875蛋白的示例参考文献，基于研究领域常见主题构建。由于FLJ12875的研究可能较为有限，建议通过学术数据库进一步验证或查阅相关基因数据库(如UniProt、NCBI Gene)。
---
1. **文献名称**：*Expression and functional characterization of recombinant human FLJ12875 protein in cancer cell lines*
**作者**：Chen L, et al.
**摘要**：本研究成功在大肠杆菌中表达并纯化了重组人FLJ12875蛋白，证实其在乳腺癌细胞中调控MAPK信号通路，促进细胞迁移和侵袭，提示其潜在的致癌作用。
2. **文献名称**：*Structural analysis of FLJ12875 reveals a novel ATP-binding motif involved in oxidative stress response*
**作者**：Yamamoto K, et al.
**摘要**：通过X射线晶体学解析FLJ12875的三维结构，发现其具有独特的ATP结合域，并在体外实验中显示重组蛋白可减轻H₂O₂诱导的细胞氧化损伤，表明其抗氧化功能。
3. **文献名称**：*Proteomic identification of FLJ12875 as a biomarker for early-stage hepatocellular carcinoma*
**作者**：Wang H, et al.
**摘要**：利用质谱技术筛选肝癌患者血清，发现FLJ12875表达显著升高。重组蛋白的体外实验证实其通过调控Wnt/β-catenin通路参与肿瘤生长，可能作为早期诊断标志物。
4. **文献名称**：*FLJ12875 knockdown inhibits angiogenesis via VEGF suppression in endothelial cells*
**作者**：Zhang R, et al.
**摘要**：研究采用siRNA沉默FLJ12875基因，发现重组蛋白的缺失导致内皮细胞中VEGF分泌减少，提示其在血管生成中的关键作用，或为抗血管治疗新靶点。
---
**注意事项**：
- 上述文献为示例，实际研究可能需要查阅真实数据库。
- 若研究有限，可扩展检索基因别名(如C12orf29)或相关通路(如代谢调控、肿瘤微环境)。
- 推荐通过PubMed或Google Scholar结合关键词(如“FLJ12875 recombinant function”)获取最新文献。
Recombinant human FLJ12875 protein is a genetically engineered form of the FLJ12875 protein, encoded by the FLJ12875 gene located on chromosome 2q33.3. This protein, also referred to as DENND6B, belongs to the DENN (differentially expressed in normal and neoplastic cells) domain-containing protein family, known for roles in membrane trafficking and GTPase signaling regulation. FLJ12875 contains a conserved DENN domain, suggesting potential involvement in vesicle transport or receptor-mediated signaling pathways. However, its precise biological function remains poorly characterized, classifying it as a "hypothetical protein" in many databases. Recombinant FLJ12875 is typically expressed in prokaryotic (e.g., *E. coli*) or eukaryotic systems (e.g., HEK293 cells) with affinity tags (e.g., His-tag) to enable purification for functional studies. Interest in this protein has emerged from bioinformatics analyses linking it to cancer progression, neurodegenerative disorders, and immune regulation, though experimental validation is limited. Current research focuses on identifying interacting partners, subcellular localization (predominantly cytoplasmic), and its regulatory effects on cellular processes like proliferation and apoptosis. The lack of structural and mechanistic data underscores its status as an understudied protein, making recombinant FLJ12875 a valuable tool for elucidating its role in basic cell biology and disease contexts.
×
